# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst David Amsellem reiterates Corcept Therapeutics (NASDAQ:CORT) with a Overweight and maintains $35 price...
Results from the CATALYST clinical trial were presented at the American Diabetes Association's 84th Scientific Sessions at ...
Truist Securities analyst Joon Lee maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and maintains $65 price target.
Corcept Therapeutics Inc. (NASDAQ: CORT) shares are trading lower Friday afternoon following a report suggesting Teva Pharmaceu...
Teva sues Corcept over mifepristone 'monopoly' for rare disorder | Reuters
Truist Securities analyst Joon Lee reiterates Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from...